WallStreetZenWallStreetZen

NASDAQ: KPTI
Karyopharm Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Karyopharm Therapeutics revenue was $148.44M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2024) ending on Sep 30, 2024 was $38.8M, down 9.4% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, KPTI annual revenue was $146.0M, with -7% growth year-over-year.

KPTI past revenue growth

How has KPTI's revenue growth performed historically?

Company
1.77%
Industry
1,119.2%
Market
37%
KPTI's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
KPTI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
KPTI's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

KPTI revenue history

Current Revenue
$148.4M
Current Earnings
-$87.5M
Current Profit Margin
-58.9%

Be the first to know when KPTI announces revenue.

KPTI Revenue History By Year

KPTI Yearly RevenueKPTI RevenueKPTI ChangeKPTI Revenue Growth
2023-12-31$146.03M-$11.04M-7.03%
2022-12-31$157.07M-$52.75M-25.14%
2021-12-31$209.82M$101.73M+94.12%
2020-12-31$108.09M$67.19M+164.31%
2019-12-31$40.89M$10.56M+34.80%
2018-12-31$30.34M$28.73M+1,790.09%
2017-12-31$1.61M$1.45M+942.21%
2016-12-31$154.00k-$96.00k-38.40%
2015-12-31$250.00k$21.00k+9.17%
2014-12-31$229.00k-$158.00k-40.83%
2013-12-31$387.00k-$247.00k-38.96%
2012-12-31$634.00k$482.00k+317.11%
2011-12-31$152.00kN/AN/A

1 of 1

Karyopharm Therapeutics Revenue FAQ

What was KPTI's revenue last quarter?

On Invalid Date, Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 2024 revenue of $38.78 million up 7.7% year over year. In the same quarter last year, Karyopharm Therapeutics's revenue was $36.01 million.

What was Karyopharm Therapeutics's revenue in 2023?

Karyopharm Therapeutics's annual revenue for the twelve months ending Dec 31, 2023 was $146.03 million, a 7.03% decrease year over year.

How much does Karyopharm Therapeutics make in a day?

Based on Karyopharm Therapeutics annual revenue for the past five years, KPTI makes an average of $362,687.12 per day.

What was Karyopharm Therapeutics's annual revenue growth in the past year?

As of Q4 2024, Karyopharm Therapeutics's revenue has grown 1.77% year over year. This is 1,117.43 percentage points lower than the US Biotechnology industry revenue growth rate of 1,119.2%. Karyopharm Therapeutics's revenue in the past year totaled $148.44 million.

How much does Karyopharm Therapeutics make in a year?

Karyopharm Therapeutics's revenue by year for the past five years is:
  • Karyopharm Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $146.03 million, a 7.03% decrease year over year.
  • Karyopharm Therapeutics's annual revenue for Dec 31, 2022 was $157.07 million, a 25.14% decrease from 2021.
  • Karyopharm Therapeutics's annual revenue for 2021 was $209.82 million, a 94.12% increase from 2020.
  • Karyopharm Therapeutics's annual revenue for 2020 was $108.09 million, a 164.31% increase from 2019.
  • Karyopharm Therapeutics's annual revenue for 2019 was $40.89 million, a 34.8% increase from 2018.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.